

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.
上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

VOLUNTARY ANNOUNCEMENT
INTENTION OF THE EXECUTIVE DIRECTOR AND
CONTROLLING SHAREHOLDER TO INCREASE SHAREHOLDING

This announcement is made by Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”) on a voluntary basis.

On August 7, 2022, the board (the “**Board**”) of directors (the “**Directors**”) of the Company has been notified by Mr. Philip Li Wang (“**Mr. Wang**”), chairman of the Board, an executive Director and controlling shareholder of the Company that he intends to use his own financial resources to increase his shareholding by having himself or his wholly-owned company acquire no more than 600,000 H Shares of the Company in the open market within approximately six months from the date of this announcement (the “**Proposed Shareholding Increase**”).

Mr. Wang informed the Board that the Proposed Shareholding Increase is based on his firm confidence in the research and development of the Company’s pipeline products, as well in recognition of the long-term investment value of the Company.

According to the information available to the Company and so far as the Directors are aware, the Company shall maintain sufficient public float of the shares in issue after completion of the Proposed Shareholding Increase and as at the date of this announcement.

Shareholders and potential investors should note that the Proposed Shareholding Increase may or may not proceed, shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company. If they are in any doubt, they should consult their professional advisers.

By order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and Executive Director

Shanghai, the People's Republic of China, August 8, 2022

As at the date of this announcement, the Board of the Company comprises Mr. Philip Li WANG as chairman and executive Director, Mr. Yunqing WANG as executive Director, Ms. Li CAI, Mr. Quan ZHOU, and Mr. Ji CHEN as non-executive Directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. George Chien Cheng LIN as independent non-executive Directors.